Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter...

New device-aided therapies (DATs) have emerged to treat people with Parkinson's disease (PwP). Our aim was to know which DATs were indicated by the neurologist and to compare the characteristics of the patients treated under real clinical practice in Spain in the year 2024.

Data collected in the DATs-PD GETM Spanish Registry were used (REDCap). This is a descriptive, observational, prospective, multicenter, clinical registry with progressive inclusion of PwP treated with a DAT in daily clinical practice conditions in more than 40 centers from Spain for 10 years. For this proposal, only data from visit V1 (indication of DAT) were analyzed, but no follow-up data. All patients with information on DAT received until 31/DEC/2024 were included.

A total of 313 PD patients (66.7 ± 9.6 years old at V2; 61.7% males) were treated with a DAT. The most frequent DAT was subcutaneous foslevodopa/foscarbidopa (fLD/fCD) (47%) followed by deep brain stimulation (DBS) (20.1%) and continuous subcutaneous apomorphine infusion (CSAI) (19.8%). Up to 23.6% had received at least one previous DAT and 47% an on-demand therapy. Differences in age, time with fluctuations and other aspects (motor status, quality of life or activities of daily living among others) were observed between different DAT groups. Specifically, patients treated with DBS were younger and had less advanced disease, whereas those who received LECIG were the most affected.

Subcutaneous therapies and DBS were the most frequent DATs (86.9%) implemented in Spain in 2024. Profile differences were detected between DAT types.